Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity

Naoki Yamakawa, Koichiro Suzuki, Yasunobu Yamashita, Takashi Katsu, Kengo Hanaya, Mitsuru Shoji, Takeshi Sugai, Tohru Mizushima

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Non-steroidal anti-inflammatory drugs (NSAIDs) achieve their anti-inflammatory effect by inhibiting cyclooxygenase activity. We previously suggested that in addition to cyclooxygenase-inhibition at the gastric mucosa, NSAID-induced gastric mucosal cell death is required for the formation of NSAID-induced gastric lesions in vivo. We showed that celecoxib exhibited the most potent membrane permeabilizing activity among the NSAIDs tested. In contrast, we have found that the NSAID rofecoxib has very weak membrane permeabilizing activity. To understand the membrane permeabilizing activity of coxibs in terms of their structure-activity relationship, we separated the structures of celecoxib and rofecoxib into three parts, synthesized hybrid compounds by substitution of each of the parts, and examined the membrane permeabilizing activities of these hybrids. The results suggest that the sulfonamidophenyl subgroup of celecoxib or the methanesulfonylphenyl subgroup of rofecoxib is important for their potent or weak membrane permeabilizing activity, respectively. These findings provide important information for design and synthesis of new coxibs with lower membrane permeabilizing activity.

Original languageEnglish
Pages (from-to)2529-2534
Number of pages6
JournalBioorganic and Medicinal Chemistry
Issue number8
Publication statusPublished - 2014 Apr 15


  • COX-2 selectivity
  • Celecoxib
  • Gastric adverse effect
  • Membrane permeabilization
  • Rofecoxib

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity'. Together they form a unique fingerprint.

Cite this